Chelsea Therapeutics (CHTP) Slashed 20%+ on Trade Resumption
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Chelsea Therapeutics (CHTP) Says Northera Meets Primary Endpoint
December 4, 2012 4:07 PM ESTChelsea Therapeutics International, Ltd. (Nasdaq: CHTP) announced positive preliminary results for Study 306B, a Phase III trial evaluating the safety and efficacy of investigational drug Northera (droxidopa) for the treatment of symptomatic neurogenic orthostatic hypotension (NOH) associated with Parkinson's Disease (PD), including achievement of the study's pre-defined,... More
Chelsea Therapeutics International (CHTP) halted, news
December 4, 2012 4:01 PM ESTChelsea Therapeutics International Ltd. (NASDAQ: CHTP) halted, news... More
